Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore Visa cards that provide rewards without the burden of annual fees. Enjoy benefits while saving money.
22,257 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Bitcoin trades near $81,000 as a decisive 72-hour window begins for the crypto market. Traders weigh ETF inflows, liq...
A CertiK report reveals 34 verified crypto wrench attacks globally, up 41% from last year. Victims’ families are incr...
AST SpaceMobile is set to unveil first-quarter results tonight. With a volatile backdrop and a slate of potential cat...
QuantumScape stock rallies on the Eagle Line milestone and early customer billings, signaling a shift from research t...
Stocks opened sharply lower on May 15, 2026, pushing the S&P 500 onto a heavier red backdrop as tech weakness and inf...
An early retiree with eight rental units weighs whether to sell one property to eliminate debt and simplify managemen...
Hyperliquid's new ETFs drew nearly $50 million in the first week, lifting the token price above $50 and signaling gro...
Nvidia's latest earnings moment features a clear signal from Jensen Huang about AI demand and strategic momentum. Thi...
Jim Cramer won’t touch POET as retail investors drive a volatile rally. This report tracks the catalysts, the bets, a...
Redwire stock swung sharply during today’s session, leaving investors with questions about its business model and gro...
Broadcom posted solid revenue growth and a solid EPS beat, but AI chip guidance disappointed some. This guide breaks ...